Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 13, 2009

Cellectis to Employ Diatos’ Drug Delivery Platform

  • Cellectis acquired the Vectocell® intracellular delivery technology from Diatos to optimize the efficacy of its drug candidates. This platform reportedly improves the performance of a therapeutic compound by enabling specific entry into the target cell compartment or organ in animals and humans.

    It is based on the fusion between the therapeutic protein and an antibody-derived peptide that facilitates passive entry into the cell. Experimental data shows that this targeting technique provokes minimal immunogenicity and thus reportedly offers excellent safety.

","DownloadsUrl":"","CompanyUrl":null,"CompanyEmail":null,"IsFavoriteItem":false,"RequestRawUrl":"/gen-news-highlights/cellectis-to-employ-diatos-drug-delivery-platform-br/78565158","HasIssueInfo":false,"IssueInfo":null}; var isAuthenticated = 'False';

Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.